射频消融与甲状腺切除术治疗良性甲状腺结节的成本效益分析
本研究通过微观模拟决策模型比较射频消融与肺叶切除术治疗良性甲状腺结节的成本效益。基础病例为45岁女性,单个30-cm3结节。结果显示射频消融为优势策略,产出21.31质量调整生命年,总成本16,563美元,而肺叶切除术为21.13质量调整生命年,总成本19,262美元。射频消融的成本效益对射频消融成本最敏感。
要点
- 射频消融治疗良性甲状腺结节比肺叶切除术更具成本效益。
- 射频消融策略在支付意愿阈值下,成本效益受射频消融成本影响最大。
- 模型假设射频消融初始成功率为78%,体积缩小率<50%者接受第二次治疗。
核心结论
- 射频消融是治疗良性甲状腺结节的一种成本效益策略,但对射频消融的成本最为敏感。
研究设计与样本
- 构建患者级状态转移微观模拟决策模型,比较射频消融与肺叶切除术治疗良性甲状腺结节。
- 基础病例为45岁女性,患有单个30-cm3结节。
- 健康效用、并发症和死亡率估计来自文献,成本使用Medicare报销数据估算。
- 进行单因素敏感性分析和概率敏感性分析(100万次模拟),支付意愿阈值设为100,000美元/质量调整生命年。
主要发现
- 射频消融假设成本为5,000美元,初始成功率为78%。
- 体积缩小率<50%的患者接受第二次射频消融治疗。
- 射频消融产出21.31质量调整生命年,总成本16,563美元;肺叶切除术产出21.13质量调整生命年,总成本19,262美元。
- 射频消融为优势策略。
- 单因素敏感性分析中,射频消融成本变化时,在支付意愿50,000美元下成本效益可持续至射频消融成本超过12,330美元,在支付意愿100,000美元下可持续至超过17,950美元。
关键数值与推荐
- 射频消融成本假设为5,000美元,初始成功率为78%。
- 体积缩小率<50%者接受第二次射频消融治疗。
- 支付意愿阈值设为100,000美元/质量调整生命年。
- 射频消融成本效益阈值:支付意愿50,000美元时为12,330美元,支付意愿100,000美元时为17,950美元。
临床怎么用
- 对于良性甲状腺结节患者,射频消融可能是一种更具成本效益的替代方案。
- 决策时应考虑射频消融的实际成本,因其对成本效益影响显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiofrequency ablation is an emerging technology in the United States to treat benign thyroid nodules. The cost-effectiveness of radiofrequency ablation in comparison with traditional thyroidectomy is unknown. METHODS: A patient-level state transition microsimulation decision model was constructed comparing radiofrequency ablation with lobectomy in the management of benign thyroid nodules. Our base case was a 45-year-old woman with a solitary 30-cm3 nodule. Estimates of health utilities, complications, and mortality were obtained from the literature, and costs were estimated using Medicare reimbursement data. The primary outcomes of interest included total cost, quality-adjusted life years, and incremental cost-effectiveness ratios. All model estimates were subjected to 1-way sensitivity analyses to identify factors that strongly influence cost-effectiveness. A probabilistic sensitivity analysis was run across 1 million simulations to gauge outcome confidence with a willingness-to-pay threshold set at $100,000/quality-adjusted life year. RESULTS: Radiofrequency ablation was assumed to cost $5,000, with an initial success rate of 78%. Patients with volume reduction ratio <50% underwent a second treatment of radiofrequency ablation. Radiofrequency ablation represented the dominant strategy, yielding 21.31 quality-adjusted life years for a total cost of $16,563 in comparison to lobectomy, which yielded 21.13 quality-adjusted life years for a total cost of $19,262. In a 1-way sensitivity analysis varying the cost of radiofrequency ablation across of range of values, the radiofrequency ablation strategy remained cost-effective until the cost of radiofrequency ablation exceeded $12,330 at willingness-to-pay $50,000 or $17,950 at willingness-to-pay $100,000. CONCLUSION: Radiofrequency ablation is a cost-effective strategy in the treatment of benign thyroid nodules but is most sensitive to the cost of radiofrequency ablation.
引用
- Kuo EJ, Oh A, Hu Y, et al. If the price is right: Cost-effectiveness of radiofrequency ablation versus thyroidectomy in the treatment of benign thyroid nodules. Surgery. 2022. PMID: 36334980. doi:10.1016/j.surg.2022.08.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。